Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab effect on small airways in severe eosinophilic asthma
NL-OMON55433Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in asthma and eosinophilic asthma (EA) comparing Reslizumab with Placebo (2 arms). Primary endpoints: Change from baseline in regional image-based hyperinflation and Change from baseline in iVaw. Started Nov 2018; status: completed.
02
Drugs
reslizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON55433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55433.